This study focuses on people who have been diagnosed with a solid tumor that contains a specific change (mutation) in the KRAS gene. One common mutation in KRAS is called G12D; participants in this study will have the G12D mutation. Slots may be available in groups of patients with pancreatic adenocarcinoma, non-small cell lung cancer, colorectal cancer, and any other solid tumor with a KRAS G12D mutation. The purpose of the study is to determine the safety and best dose of an experimental drug called VS-7375 in these patients.VS-7375 is a drug that was specifically developed to target the G12D mutation in KRAS. The goal is to block the effects of this mutation, slowing down or stopping the growth of cancer cells without affecting normal cells. Study procedures include physical exams, blood and urine sample lab collection, electrocardiogram, imaging scans, biopsy, and drug administration. Researchers also aim to determine whether VS-7375 will provide a treatment benefit, as well as whether the drug can safely be combined with other treatments that are already approved by the U.S. Food and Drug Administration (FDA) to treat certain types of cancers.

• CS Cancer at Cedars-Sinai Medical Center : Shannon Cyhan
• CS Cancer at The Angeles Clinic and Research Institute : Shannon Cyhan